Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
Status:
Completed
Trial end date:
2000-09-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Conduct a randomized, double blind, placebo controlled, parallel study of the
atypical neuroleptic risperidone (RIS) in the treatment of children and adults with moderate
to severe Tourette Syndrome.
II. Evaluate further the safety of RIS in this population.